<DOC>
	<DOCNO>NCT00632502</DOCNO>
	<brief_summary>4-Week Safety Study Subjects Neutrophilic Asthma</brief_summary>
	<brief_title>Neutrophilic Asthma Study With Navarixin ( MK-7123 , SCH 527123 ) ( MK-7123-017 ) ( COMPLETED )</brief_title>
	<detailed_description>Effect treatment navarixin ( MK-7123 , SCH 527123 ) sputum neutrophil asthma symptom</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>18 &lt; =70 year age , either sex , race . Induced sputum neutrophil count &gt; =40 % total white blood cell &lt; 10 million/mL Screening . Documented diagnosis asthma ( within past 5 year ) , determine least one following : &gt; =12 % 200 mL improvement Forced Expiratory Volume 1 second ( FEV1 ) postbronchodilator , and/or airway hyperresponsiveness ( eg , positive methacholine challenge &lt; 8 mg/mL ) . Nonsmoker previous smoker cumulative smoke history le 20 packyears ( packyear = 20 cigarette smoke daily 1 year ) . Previous smoker may smoke within 1 year prior Screening . Must exacerbation asthma 4 week prior Screening must stable medication regimen asthma least 4 week prior Screening . Must receive &gt; =800 mcg/day beclomethasone dipropionate ( BDP ) equivalent least 3 month prior Screening ( stable dose least 4 week prior Screening ) . Must willing give write informed consent participate study Must capable comply dose regimen , adhere visit schedule , participate treatment procedure , include sputum induction . Female subject childbearing potential must negative serum pregnancy test Screening must use medically acceptable , highly effective , adequate form birth control ( ie , failure rate &lt; 1 % per year use consistently correctly ) prior Screening agree continue use study ( Screening Treatment Periods ) . Medically acceptable , highly effective form birth control hormonal implant , oral contraceptive , medically acceptable prescribed intrauterine device ( IUDs ) , monogamous relationship male partner vasectomy . Female subject childbearing potential must medical record surgically sterile ( eg , hysterectomy , tubal ligation ) , least 1 year postmenopausal . Absence menses least 1 year indicate female postmenopausal . A female subject encourage continue use highly effective method birth control 30 day follow end treatment . Male subject must agree use adequate form contraception duration study agree sexual relation woman use highly effective birth control method . Chronic Obstructive Pulmonary Disease ( COPD ) /other relevant lung disease ( asthma ) . 4 week prior to/or Screening : upper/lower respiratory tract infection . Prohibited medication receive recently indicate washout prior Screening Screening : Inadequate amount difficulty produce sputum . Screening : Sputum neutrophil count 10 million/mL . Screening : peripheral blood neutrophil ( PBN ) count &lt; 3000/ÂµL . Postbronchodilator FEV1 &lt; 1L . Clinically significant chronic infectious disease ( ) ( eg , Human Immunodeficiency Virus [ HIV ] , hepatitis B C ) . Allergy/sensitivity study drug/excipients . Breastfeeding , pregnant/intends become pregnant study . Requiring mechanical ventilation respiratory event within 6 month Screening . Medical condition ( ) ( eg , hematologic , cardiovascular , renal , hepatic , neurologic , metabolic ) medication may interfere effect study medication . Within 30 day Screening : investigational drug . Participation clinical study . Part staff personnel involve study . Family member investigational study staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>